Clinical Trials Browser

Phase 1/2 × OTHER_GOV × Leukemia × Clear all

NCT07135466 2026-01-16

A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma